Chemistry:Rimostil
Rimostil (developmental code name P-081) is a dietary supplement and extract of isoflavones from red clover which was under development by Kazia Therapeutics (formerly Novogen) for the prevention of postmenopausal osteoporosis and cardiovascular disease and for the treatment of menopausal symptoms and hyperlipidemia but was never approved for medical use.[1][2][3][4][5] It is enriched with isoflavone phytoestrogens such as formononetin, biochanin A, daidzein, and genistein, and is proposed to act as a selective estrogen receptor modulator, with both estrogenic and antiestrogenic effects in different tissues.[3][4][5] The extract reached phase II clinical trials for cardiovascular disorders, hyperlipidemia, and postmenopausal osteoporosis prior to the discontinuation of its development in 2007.[1]
See also
References
- ↑ 1.0 1.1 "P 081 - AdisInsight". https://adisinsight.springer.com/drugs/800012806.
- ↑ "Therapeutic potential of oestrogen receptor ligands in development for osteoporosis". Expert Opin Emerg Drugs 6 (1): 137–54. April 2001. doi:10.1517/14728214.6.1.137. PMID 15989501.
- ↑ 3.0 3.1 "Phytoestrogens: a review of the present state of research". Phytother Res 17 (8): 845–69. September 2003. doi:10.1002/ptr.1364. PMID 13680814.
- ↑ 4.0 4.1 "The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism". Menopause 8 (4): 259–65. 2001. doi:10.1097/00042192-200107000-00007. PMID 11449083.
- ↑ 5.0 5.1 "Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial". JAMA 290 (2): 207–14. July 2003. doi:10.1001/jama.290.2.207. PMID 12851275.
External links
 |  |
